Pharmaceutical Group
AstraZeneca Invests $2 Billion in CSPC’s Lipid-Lowering Therapy
AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment
Actionable Insights Powered by AI
AstraZeneca, CSPC Pharmaceutical Group, lipid-lowering therapy, Lp(a) disruptor, cardiovascular disease, pharmaceutical investment